Medpace Holdings, Inc.
MEDPHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Medpace Holdings, Inc. (MEDP) is listed under Diagnostics & Research. With a market capitalization of $16.50B, it sits in large-cap territory. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
Market Cap
$16.50B
Beta
1.15
P/E (TTM)
34.72
P/E (Fwd)
30.62
EPS (TTM)
$17.03
EPS (Fwd)
$19.31
ROE
162.2%
ROA
20.1%
Cash
$502.7M
Total Debt
$144.1M
Free CF
$510.4M
52W Change
21.8%
Annual Financials
Cash vs Debt
Where MEDP stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, MEDP finished 18.88% above its 150-day moving average ($499.67) and 14.06% above its 200-day moving average ($520.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MEDP overbought or oversold?
At the September 1, 2026 close, MEDP's RSI(14) was 45.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Medpace Holdings, Inc. holds $502.7M in cash against $144.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $510.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 162.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 20.1% further supports the picture of efficient asset utilization. Revenue has grown from $1.46B (2022) to $2.53B (2025), reflecting a 73% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Medpace Holdings, Inc. and its sector.